Christensenella spp. based Microbiome Therapeutic Research Services
In the rapidly evolving landscape of the human microbiome, few discoveries have generated as much excitement as Christensenella. Often hailed as the "heritable microbe of health," this genus represents a paradigm shift in how we approach metabolic disorders, obesity, and longevity. Unlike transient probiotics, Christensenella species function as keystone taxa—foundational architects of a healthy gut ecosystem that are strongly associated with lean phenotypes and robust metabolic regulation. For biopharmaceutical developers, Christensenella represents a high-potential candidate for Live Biotherapeutic Products (LBPs). However, its strict anaerobic nature and complex nutritional requirements present significant hurdles in preclinical development. Creative Biolabs bridges this gap. We provide a fully integrated platform—from strain isolation to in vivo efficacy validation—empowering you to harness the therapeutic power of Christensenella and accelerate your path to IND filing.
Overview: Christensenella spp. in Microbiome Therapeutics
Christensenella is a genus of Gram-negative, non-spore-forming, strictly anaerobic bacteria belonging to the family Christensenellaceae. First described in 2012, it has quickly become a focal point of microbiome research due to its unique heritability—human genetics play a larger role in determining its abundance than diet alone.
Epidemiological studies consistently show a strong negative correlation between Christensenella abundance and Body Mass Index (BMI). Individuals with high levels of Christensenella are significantly less likely to be obese or suffer from metabolic syndrome. Furthermore, this genus is enriched in centenarians, linking it to healthy aging. Its therapeutic mechanism involves the modulation of host metabolism, reinforcement of the intestinal barrier, and the production of beneficial metabolites like short-chain fatty acids (SCFAs).
Explore Our Key Species Focus
Explore our specialized research platforms for the three most critical species in this genus.
The Flagship of Metabolic Health. As the type species of the genus, C. minuta is the most extensively studied. It is directly causal in reducing adiposity and weight gain. Our research indicates it plays a pivotal role in modulating glucose homeostasis and lipid metabolism.
The Bioactive Modulator. A strictly anaerobic species isolated from human clinical samples, C. timonensis is gaining traction for its interaction with intestinal epithelial cells. It is currently being investigated for its specific bile acid transformation capabilities and potential immunomodulatory effects.
The Barrier Guardian. Emerging research positions C. tenuis as a critical player in alleviating endotoxemia. By modifying bile acids and inhibiting lipopolysaccharide (LPS) translocation, it helps prevent systemic inflammation often seen in metabolic diseases.
Our Preclinical Services
We specialize in the handling of strict anaerobes, offering end-to-end support for Christensenella drug discovery.
Metabolic Profiling: Quantification of SCFA production (Acetate, Butyrate) using GC-MS.
Bile Salt Hydrolase (BSH) Activity: Screening strains for their ability to deconjugate bile acids, a key factor in cholesterol lowering.
Barrier Integrity Assays: Using Caco-2/HT-29 co-cultures to measure Transepithelial Electrical Resistance (TEER) upon exposure to bacterial supernatants.
Christensenella is a Gram-negative, strictly anaerobic genus of bacteria first discovered in the human gut. Christensenella massiliensis was isolated from human stool specimen from a 66-year-old patient.
Christensenella is a Gram-negative, strictly anaerobic genus of bacteria first discovered in the human gut. Christensenella massiliensis was isolated from human stool specimen from a 66-year-old patient.
This product contains high-quality, intact genomic DNA isolated from Christensenella hongkongensis Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Research Applications: From Dysbiosis to Therapeutics
Our CRO services are designed to validate the therapeutic potential of Christensenella strains across several high-impact disease areas.
Obesity and Metabolic Syndrome
The primary application of Christensenella spp. is the treatment of obesity. Research has demonstrated that Christensenella can significantly reduce weight gain in diet-induced obesity (DIO) models. It alters the host's energy harvest by modulating the gut metabolome, reducing visceral fat accumulation, and lowering triglyceride levels.
Type 2 Diabetes and Glucose Regulation
Low abundance of Christensenella is a hallmark of Type 2 Diabetes (T2D). Restoring these populations has shown promise in improving insulin sensitivity. Through the production of acetate and butyrate, Christensenella influences the gut-brain axis and GLP-1 secretion, helping to regulate blood glucose levels.
Inflammatory Bowel Disease (IBD)
Patients with Crohn's disease and Ulcerative Colitis often exhibit a depletion of Christensenellaceae. By strengthening tight junctions and reducing the translocation of inflammatory pathogens, Christensenella helps restore gut barrier integrity (leaky gut) and dampen chronic intestinal inflammation.
Longevity and Healthy Aging
High abundance of this genus is a biomarker for longevity. It mitigates "inflammaging"—the chronic, low-grade inflammation associated with aging—thereby promoting a healthier metabolic profile in the elderly.
Why Choose Us?
Developing a "Next-Generation Probiotic" requires more than just standard microbiology; it requires deep expertise in anaerobic ecology.
Strict Anaerobic Expertise
We have overcome the "unculturable" barrier. Our proprietary media and handling protocols ensure high viability of Christensenella species, which is the biggest bottleneck in this field.
Translational Focus
Our study designs are not just academic; they are built to meet guidelines for Live Biotherapeutic Products (LBPs), ensuring your data is IND-ready.
Customized Lead Optimization
We don't just test strains; we help you improve them. From directed evolution to formulation stability testing (lyophilization optimization), we ensure your strain survives from the lab to the patient.
Partner with Us for the Future of Medicine
The correlation between Christensenella and human health is undeniable, but translating this association into a viable therapy requires precision, patience, and technical excellence. Whether you are a biotech startup looking for proof-of-concept data or a pharmaceutical giant optimizing a strain for clinical trials, our specialized Christensenella research platform is your competitive advantage.
Why is Christensenella considered a "Next-Generation Probiotic"?
Unlike traditional probiotics (e.g., Lactobacillus or Bifidobacterium), Christensenella is a commensal gut bacterium that is strictly anaerobic and highly heritable. It represents a new wave of therapeutics (LBPs) targeted at specific disease mechanisms like metabolic regulation, rather than general gut health.
Is Christensenella safe for therapeutic use?
While it is a commensal bacterium found in healthy humans, regulatory safety assessment is rigorous. Our preclinical services include full genomic safety profiling (checking for virulence factors and antibiotic resistance) and in vivo toxicity studies to ensure safety for clinical trials.
Can you help with the CMC (Chemistry, Manufacturing, and Controls) aspect?
Yes. One of the biggest challenges with Christensenella is maintaining viability during manufacturing. We offer process development services to optimize fermentation conditions and cryoprotectants for stable, high-yield production.
How do you measure the efficacy of Christensenella in obesity?
We use a multi-parametric approach. In mice, we measure body weight, visceral fat pad weight, adipocyte size (histology), serum lipids (cholesterol, triglycerides), and glucose/insulin tolerance. We also sequence the gut microbiome to see how Christensenella modulates the surrounding community.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
